A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy.

Since the advent of triple combination antiretroviral therapy in 1996, the prognosis of HIV-infected persons has improved drastically. The clinical benefits of HAART derive from producing sustained viral load suppression and CD4 gains. The major drawbacks of the first HAART regimens were common adverse events and high pill burden, which resulted in difficult drug adherence and led to frequent discontinuations and selection of drug resistance.